These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 16513092)
1. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Hancock AA Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092 [TBL] [Abstract][Full Text] [Related]
7. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Leurs R; Bakker RA; Timmerman H; de Esch IJ Nat Rev Drug Discov; 2005 Feb; 4(2):107-20. PubMed ID: 15665857 [TBL] [Abstract][Full Text] [Related]
8. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. Wieland K; Bongers G; Yamamoto Y; Hashimoto T; Yamatodani A; Menge WM; Timmerman H; Lovenberg TW; Leurs R J Pharmacol Exp Ther; 2001 Dec; 299(3):908-14. PubMed ID: 11714875 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists. Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553 [TBL] [Abstract][Full Text] [Related]
10. Several down, a few to go: histamine H3 receptor ligands making the final push towards the market? Kuhne S; Wijtmans M; Lim HD; Leurs R; de Esch IJ Expert Opin Investig Drugs; 2011 Dec; 20(12):1629-48. PubMed ID: 21992603 [TBL] [Abstract][Full Text] [Related]
11. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995 [TBL] [Abstract][Full Text] [Related]
12. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain. Sadek B; Elz S; Pertz HH; Stark H; Schunack W Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060 [TBL] [Abstract][Full Text] [Related]
13. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone. Watanabe M; Kobayashi T; Hirokawa T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S Org Biomol Chem; 2012 Jan; 10(4):736-45. PubMed ID: 22120611 [TBL] [Abstract][Full Text] [Related]
14. Histamine H3 receptor as a drug discovery target. Berlin M; Boyce CW; Ruiz Mde L J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081 [No Abstract] [Full Text] [Related]
16. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511 [TBL] [Abstract][Full Text] [Related]
17. [The histamine H(3) receptor: a target for new drugs]. Arrang JM Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930 [TBL] [Abstract][Full Text] [Related]
18. A new class of histamine H3 receptor antagonists derived from ligand based design. Roche O; RodrÃguez Sarmiento RM Bioorg Med Chem Lett; 2007 Jul; 17(13):3670-5. PubMed ID: 17498953 [TBL] [Abstract][Full Text] [Related]
19. Histamine H3 and H4 receptors as novel drug targets. Tiligada E; Zampeli E; Sander K; Stark H Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107 [TBL] [Abstract][Full Text] [Related]
20. Constitutive activity of the histamine H3 receptor. Arrang JM; Morisset S; Gbahou F Trends Pharmacol Sci; 2007 Jul; 28(7):350-7. PubMed ID: 17573125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]